• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BioIVT introduces new products and services

BioIVT introduces new products and services

November 28, 2017
CenterWatch Staff

BioIVT, a provider of biospecimens and related services, is launching a new line of products and services to improve safety, efficacy and toxicity testing for skin care products, cosmetics and topical medications.

“As the demand for personal skin care products increases—whether they are applied for anti-aging, hydration, wound healing or UV protection purposes—so does the need for better safety, efficacy and toxicity testing systems. The same holds true for new cosmetics and topical medications,” said Dr. Christopher Black, senior vice president of ADME-Tox at BioIVT. “At BioIVT, we are endeavoring to provide researchers in those fields with biological systems that allow them to more clearly understand the disposition of topical applications and their effects on normal and disease-affected skin.”

BioIVT now provides a wide range of skin products for safety, efficacy and toxicity testing. They include control tissue; disease-state skin punches for acne, atopic dermatitis, eczema, psoriasis and vitiligo; primary cell lines, such adipocytes, fibroblasts, keratinocytes, and melanocytes; and subcellular solutions. It also provides custom processing of skin samples and DNA/RNA extraction.

In addition, the company offers cell-based assay services. BioIVT works with a range of primary and immortalized skin cell lines and is able to produce high quality, phenotypically-relevant data. Its assays assess a variety of cell responses including cell toxicity, mitochondrial dysfunction, cell proliferation (ATP/MTT), oxidative stress and DNA damage.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing